NEW YORK and HAIKOU CITY, China, Nov. 5 China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) whichdevelops, manufactures, and markets generic and branded bio-pharmaceuticalproducts in China, today announced it will release its third Quarter 2008results on Friday, November 7, 2008. In conjunction, the Company will host anearning conference call at 10:00 a.m. EST on Friday, November 7, 2008 todiscuss these results.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr.Xinhua Wu, Chief Financial Officer, and Ms. Sara Ephraim, Vice President ofthe company's IR firm, The Ruth Group, will be hosting the call. Toparticipate in the conference call, please dial 1-800-591-6945 ten minutesprior to the scheduled conference call time. International callers should dial1-617-614-4911. The conference pass code is 57906502.
If you are unable to participate in the call at this time, a replay willbe available on Friday, November 7 at 12:00 p.m. EST, through Friday, November14. To access the replay, please dial 1-888-286-8010. International callersshould dial 1-617-801-6888. The conference pass code is 19590263. Thisconference call will be broadcast live over the Internet and can be accessedby clicking this link:http://phx.corporate-ir.net/playerlink.zhtml?c=145098&s=wm&e=2018680 . Areplay will also be available shortly after the call on China Pharma' websitehttp://www.chinapharmaholdings.com .
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a biopharmaceutical company with rapidlygrowing profit that develops, manufactures, and markets treatments for a widerange of high incidence and high mortality conditions in China, includingcardiovascular, CNS, infectious, and digestive diseases. The Company'scost-effective, high margin business model is driven by market demand andsupported by 8 scalable GMP-certified product lines covering the major dosageforms. In addition, the Company has a broad and expanding distributionnetwork across 30 provinces, municipalities and autonomous regions. TheCompany is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co.,Ltd (Helpson), located in Haikou City, Hainan Province, China, is a whollyowned subsidiary of China Pharma Holdings, Inc. For more information aboutChina Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement: Certain statements in this press release and oralstatements made by China Pharma on its conference call in relation to thisrelease, constitute forward-looking statements for purposes of the safe harborprovisions under The Private Securities Litigation Reform Act of 1995. Anystatements set forth above that are not historical facts are forward-lookingstatements that involve risks and uncertainties that could cause actualresults to differ materially from those in the forward-looking statements,which may include, but are not limited to, such factors as unanticipatedchanges in product demand, increased competition, failure to obtain ormaintain intellectual property protection, downturns in the Chinese economy,uncompetitive levels of research and development, failure to obtain regulatoryapprovals, and other information detailed from time to time in the Company'sfilings and future filings with the United States Securities and ExchangeCommission. The forward-looking statements made herein speak only as of thedate of this press release and the Company undertakes no duty to update anyforward-looking statement to conform the statement to actual results orchanges in the company's expectations.For more information, please contact: China Pharma Holdings, Inc. Diana Huang Tel: +86-898-6681-1730 Email: [email protected]
The Ruth Group Sara Ephraim Tel: +1-646-536-7002 Email: [email protected]
SOURCE China Pharma Holdings, Inc.